Regulation — pharma-specific
EMA Reflection Paper on AI — in the medicinal-product lifecycle
The 2023 EMA Reflection Paper (and 2024 Concept Paper) frame AI as an in-scope tool for both trial conduct and MAA-supporting evidence. Sponsors preparing for EMA scientific advice or centralised MAA submission need to answer AI-monitoring questions with dated independent evidence — not vendor screenshots.
What the reflection paper actually says
"The use of AI and ML in the medicinal product lifecycle … requires that the tools employed are validated, that their limitations are recognised, and that human oversight is maintained at all critical steps."
EMA Reflection Paper on the Use of Artificial Intelligence in the Lifecycle of Medicines (2023 draft)
"Marketing authorisation applicants must be able to explain the AI/ML-based components of their applications … and to justify their impact on the benefit-risk assessment."
EMA Reflection Paper — MAA explainability expectation
What this means in plain English
Three EMA expectations that reach directly into the trial-AI monitoring conversation:
- Validation on file. AI tools used in trial conduct or MAA-supporting analysis must be validated + limitations documented.
- Human oversight at critical steps. AI-driven eligibility is a critical step. Human oversight there is more than an investigator's rubber-stamp.
- Explainability at MAA. The applicant must be able to explain AI-based components + justify their benefit-risk impact.
What triggers the exposure in the sample
Silent P3 exclude-lane drift from 22% to 75% is precisely the pattern EMA rapporteurs watch for when reviewing AI-supported eligibility. "Human oversight at critical steps" is hard to defend if the drift ran silently for 45+ days. And at MAA, an unaddressed representation skew becomes a benefit-risk explainability question EMA reviewers will surface.
What the $499 Snapshot shows against this rule
- Independent AI-monitoring validation record — the "tools validated + limitations recognised" evidence
- Timestamped drift-detection log — the human-oversight-critical-step evidence
- Per-patient-group differential + representative-population quantification — direct input to MAA explainability
- Signed independent-verifier declaration — separate plane from sponsor + CRO + AI vendor
See the independent-verifier declaration →
$499 Snapshot. 3 business days.
Independent-verifier determination scoped to your sponsor's AI surface + 3 fix-first items + signed declaration.
Buy $499
Snapshot credit applies to Baseline ($2,500) or Enterprise Attestation ($35-55K) upgrade within 30 days.